Last update 30 Sep 2025

AZD0240

Overview

Basic Info

Drug Type
TCR-T Cell therapy
Synonyms
AZD-0240
Target
KRAS G12D
Action
inhibitors
Mechanism
KRAS G12D inhibitors(GTPase KRas G12D inhibitors)
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [2]
Active Indication
Adenocarcinoma of large intestineEndometrial CarcinomaNon-Small Cell Lung Cancer+ [2]
Inactive Indication-
Originator Organization
Neogene Therapeutics, Inc.Neogene Therapeutics, Inc.
AstraZeneca, Inc.
Active Organization
AstraZeneca PLCAstraZeneca PLCNeogene Therapeutics, Inc.Neogene Therapeutics, Inc.
AstraZeneca, Inc.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with AZD0240
NCT06218914
/ RecruitingPhase 1
Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T Cells Recognizing KRAS Mutations in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors
100 Clinical Results associated with AZD0240
Login to view more data
100 Translational Medicine associated with AZD0240
Login to view more data
100 Patents (Medical) associated with AZD0240
Login to view more data
100 Deals associated with AZD0240
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adenocarcinoma of large intestinePhase 1
United States
AstraZeneca PLCAstraZeneca PLC
22 Mar 2024
Endometrial CarcinomaPhase 1
United States
AstraZeneca PLCAstraZeneca PLC
22 Mar 2024
Non-Small Cell Lung CancerPhase 1
United States
AstraZeneca PLCAstraZeneca PLC
22 Mar 2024
Pancreatic Ductal AdenocarcinomaPhase 1
United States
AstraZeneca PLCAstraZeneca PLC
22 Mar 2024
NeoplasmsPreclinical
United States
AstraZeneca, Inc.
28 Apr 2025
NeoplasmsPreclinical
Netherlands
Neogene Therapeutics, Inc.Neogene Therapeutics, Inc.
28 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free